Improving the Predictive Value of Preclinical Studies in Support of Radiotherapy Clinical Trials.

ABSTRACT: There is an urgent need to improve reproducibility and translatability of preclinical data to fully exploit opportunities for molecular therapeutics involving radiation and radiochemotherapy. For in vitro research, the clonogenic assay remains the current state-of-the-art of preclinical assays, whereas newer moderate and high-throughput assays offer the potential for rapid initial screening. Studies of radiation response modification by molecularly targeted agents can be improved using more physiologic 3D culture models. Elucidating effects on the cancer stem cells (CSC, and CSC-like) and developing biomarkers for defining targets and measuring responses are also important. In vivo studies are necessary to confirm in vitro findings, further define mechanism of action, and address immunomod

SUBMITTER: Coleman CN 

PROVIDER: S-EPMC4930691 | biostudies-literature | 2016 Jul

REPOSITORIES: biostudies-literature